Published in Obesity and Diabetes Week, November 10th, 2003
The data reported describe formulation, preclinical, and clinical studies conducted to date. Using Nastech's proprietary formulation science and high- throughput in vitro screening system, a nasal formulation was developed that increases the delivery of peptides such as PYY by more than 100-fold. Preclinical studies designed to characterize the tolerance of the naturally...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.